Renaissance Technologies LLC Has $11.63 Million Stake in LivaNova PLC $LIVN

Renaissance Technologies LLC lifted its position in LivaNova PLC (NASDAQ:LIVN) by 15.7% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 183,000 shares of the company’s stock after buying an additional 24,900 shares during the quarter. Renaissance Technologies LLC’s holdings in LivaNova were worth $11,631,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LIVN. SG Americas Securities LLC increased its stake in shares of LivaNova by 83.9% during the 4th quarter. SG Americas Securities LLC now owns 24,257 shares of the company’s stock worth $1,493,000 after purchasing an additional 11,066 shares during the last quarter. Exchange Traded Concepts LLC bought a new position in shares of LivaNova during the 4th quarter valued at $970,000. Peregrine Capital Management LLC acquired a new stake in shares of LivaNova in the 4th quarter valued at $3,830,000. F m Investments LLC boosted its holdings in LivaNova by 46.9% in the fourth quarter. F m Investments LLC now owns 114,458 shares of the company’s stock worth $7,043,000 after purchasing an additional 36,543 shares in the last quarter. Finally, Tudor Investment Corp ET AL bought a new stake in LivaNova in the third quarter worth $1,746,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on LIVN. Zacks Research upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Mizuho increased their price objective on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Freedom Capital upgraded LivaNova to a “hold” rating in a report on Tuesday, June 30th. Finally, KeyCorp upped their target price on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.38.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares in the company, valued at approximately $547,521. This represents a 19.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.35% of the stock is owned by company insiders.

LivaNova Stock Performance

LIVN opened at $80.14 on Friday. The stock has a market cap of $4.40 billion, a PE ratio of 41.10 and a beta of 0.86. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 1 year low of $41.01 and a 1 year high of $85.27. The stock’s 50 day simple moving average is $79.09 and its 200-day simple moving average is $70.13.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. The firm had revenue of $362.26 million during the quarter, compared to analysts’ expectations of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period last year, the business earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Sell-side analysts forecast that LivaNova PLC will post 3.73 EPS for the current year.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.